Project Grant R44HL128670

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $894,735 to develop a novel positron emission tomography (PET) imaging agent, [18F]fluoromannitol, to diagnose osteomyelitis (bone infection) in patients with sickle cell disease. The goal is to create a clinically translatable PET imaging tool that can specifically identify bacterial infection in the body, which can...

This federal Project Grant award of $225,101 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancies in sickle cell disease patients. The key objectives of this 2-year project are to: 1) Perform experiments to understand how increased oxidative stress and DNA damage in hematopoietic stem and progenitor cells lead to the development of clonal...

This Phase 2 clinical trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), investigates intravenous L-citrulline as an adjunctive therapy to reduce opioid use and hospital length of stay in sickle cell disease patients experiencing vaso-occlusive crises (VOC). The randomized, double-blind, placebo-controlled study will enroll sickle cell patients and assess whether citrulline supplementation—which enhances nitric...

Federal Grant Award Summary Reneurogen LLC received a $1,045,688 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 22, 2025, with completion targeted for June 30, 2027. The award funds development of KYC (N-acetyl-lysyltyrosylcysteine amide), a novel first-in-class drug candidate designed to treat vasculopathy, vasocongestion, vaso-occlusive crisis (VOC), and pain associated with...

The Ohio State University received a $765,931 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 22, 2025, with completion targeted for July 31, 2030. The grant supports PF-GUIDE (Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults with Sickle Cell Disease), a multi-center hybrid type I effectiveness-implementation trial designed to deliver evidence-based clinical...

Federal Project Grant Award Summary Duke University's Office of Research Administration received a $444,125 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 24, 2025, with completion targeted for June 30, 2027. The research project investigates the modulation of neutrophil function by red cell exchange (RCE) procedures in sickle cell disease (SCD) patients. The award...

Federal Project Grant Award Summary New Health Sciences, Inc. (operating as Hemanext Inc.) received a $1.02 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 5, 2025, with a completion date of August 31, 2028. The award funds a clinical efficacy trial assessing hypoxic red blood cell (HRBC) transfusions processed through Hemanext's proprietary HemaNEXT ONE system compared to...

Federal Cooperative Agreement Summary Award Overview Sesh Incorporated received a $406,500 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on September 12, 2025, with completion targeted for August 31, 2026. The award supports the development and commercialization of RELOAD (Restriction Element Loss of Allele Detection), a cell-free DNA (cfDNA) next-generation sequencing (NGS) liquid biopsy assay...